schizophrenia

MILAN, Italy and MORRISTOWN, N.J. September 25, 2026 — Newron Pharmaceuticals announced that the U.S. clinical hold on enrollment...

Titusville, New Jersey, U.S., September 21, 2026 Johnson & Johnson has announced positive topline results from a pivotal Phase...

Tel Aviv, Israel, September 18, 2026 Teva Pharmaceuticals has announced new findings from a study examining the factors that...

Shanghai and Hong Kong, PRC, September 21, 2026 Antengene Corporation Limited has announced the dosing of the first patient...

Tel Aviv, Israel, September18, 2026 Teva Pharmaceutical Industries Ltd. has announced new post hoc clinical data for TEV-‘749, its...

Titusville, New Jersey, U.S., September 8, 2026 Johnson & Johnson is set to present new clinical and real-world evidence...

MILAN, Italy and MORRISTOWN, N.J., September 2, 2026 Newron Pharmaceuticals S.p.A. announced completion of screening for enrollment in its...

Naarden, The Netherlands, August 19, 2026 Kynexis, a clinical-stage biotechnology company developing therapies for cognitive disorders, has raised an...

Worcester, Massachusetts, August 17, 2026 Leal Therapeutics, a clinical-stage biopharmaceutical company developing neuro-metabolic therapeutics for central nervous system disorders,...

NESS ZIONA, Israel, August 12, 2026 Mapi Pharma Ltd. announced initial clinical results from its ongoing Phase I/IIa study...